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Background: Calls have been made for governments to adopt a cohesive approach to rare diseases through the
development of national plans. At present, Australia does not have a national plan for rare diseases. To progress
such a plan an inaugural Australian Rare Diseases Symposium was held in Western Australia in April 2011. This paper
describes the key issues identified by symposium attendees for the development of a national plan, compares
these to the content of EUROPLAN and national plans elsewhere and discusses how the outcomes might be
integrated for national planning.
Methods: The symposium was comprised of a series of plenary sessions followed by workshops. The topics
covered were; 1) Development of national plans for rare diseases; 2) Patient empowerment; 3) Patient care, support
and management; 4) Research and translation; 5) Networks, partnerships and collaboration. All stakeholders within
the rare diseases community were invited to participate, including: people affected by rare diseases such as
patients, carers, and families; clinicians and allied health practitioners; social and disability services; researchers;
patient support groups; industry (e.g. pharmaceutical, biotechnology and medical device companies); regulators
and policy-makers.
Results: All of these stakeholder groups were represented at the symposium. Workshop participants indicated the
need for a national plan, a national peak body, a standard definition of ‘rare diseases’, education campaigns,
lobbying of government, research infrastructure, streamlined whole-of-lifetime service provision, case co-ordination,
early diagnosis, support for health professionals and dedicated funding.
Conclusions: These findings are consistent with frameworks and initiatives being undertaken internationally (such
as EUROPLAN), and with national plans in other countries. This implies that the development of an Australian
national plan could plausibly draw on frameworks for plan development that have been proposed for use in other
jurisdictions. The translation of the symposium outcomes to government policy (i.e. a national plan) requires the
consideration of several factors such as the under-representation of some stakeholder groups (e.g. clinicians) and
the current lack of evidence required to translate some of the symposium outcomes to policy options. The
acquisition of evidence provides a necessary first step in a comprehensive planning approach.
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It has been argued that government responses to the needs
of people affected by rare diseases have been sub-optimal
[1]. This is despite the cumulative prevalence of rare dis-
eases; the severity of impact on many people living with
rare diseases, including carers and families and on publicly
funded services. To address the argued lack of response,
and since rare diseases share many common features [2],
calls have been made for governments to adopt a more co-
hesive approach to rare diseases through development of
National plans [2-8]; including calls in Australia [9-13].
National plans for rare diseases are official strategic docu-
ments comprised of specific priorities, actions, budgets and
timetables that have been endorsed by governments [6].
National plans are seen as vehicles that provide frameworks
incorporating a coordinated “whole-of-government” ap-
proach to rare diseases, as opposed to a “piece-meal”
approach. These plans outline a cohesive clinical, public
health and disability service approach to rare diseases that
addresses prevention, timely diagnosis, early intervention,
appropriate access to treatments and rehabilitation [3,5].
Such plans do exist internationally and provide guidance
on how current services can be better integrated and how
the translation of new knowledge relevant to the care and
overall well-being of people living with a rare disease can
be better informed by epidemiology, health economics, re-
search to inform health and disability service planning, the
provision of and access to services and information and
industry policy [6].
The adoption of national plans, with dedicated funding,
first occurred in France [14,15] with the second French Na-
tional Plan released in 2011 and National plans have been
adopted in other European countries including Belgium,
Bulgaria, Czech Republic, Germany, Greece, Luxembourg,
Portugal, Romania and Spain [16]. The European Union
has recommended that all member states should have a
national strategy for rare diseases by 2013. In 2008 the
European Project for Rare Diseases National Plans Develop-
ment (EUROPLAN) was funded by the European Commis-
sion. The aim of EUROPLAN is to provide an evidence-
based framework for developing national plans. It identifies
models and strategies that have been effective for addressing
rare diseases, and outlines recommendations for actions to
include in national plans. EUROPLAN also contains a list of
indicators for implementing and monitoring national plans
for rare diseases.
At present, Australia does not have a national plan for
rare diseases. There are policies and plans that address the
health and social needs of people living with chronic dis-
eases, at both the state and federal government level. While
these align with some of the unmet needs among the rare
disease community, they do not necessarily cater for the
range of needs specific to people living with rare diseases
such as (lack of) access to timely diagnosis, diseasemanagement and access to treatment and rehabilitation
programs. [11] Recognition of the need for an Australian
national plan for rare diseases has gained momentum in
recent years. The first published Australian call for better
co-ordination in rare diseases came from the general prac-
tice sector [11] followed more recently by the Australian
Paediatric Surveillance Unit (APSU http://www.apsu.org.
au) [10], a research organisation that facilitates the study of
rare childhood diseases. In 2009 APSU, with a small grant
from the Australia Research Alliance for Children and
Youth (ARACY), established a working group of 24 mem-
bers to draft an outline for a national plan [17]. This plan
was modeled on the French national plan [14] and called
for actions related to awareness, education, improved ac-
cess to health care, research, information collection and dis-
semination, a peak national body and advocacy.
To progress a national plan for Australia an inaugural
Australian Rare Diseases Symposium was held in Western
Australia in April 2011. The Symposium was structured
around a series of plenary sessions. These were each fol-
lowed by workshops where stakeholders discussed issues
they deemed relevant to the development of a national
plan. Stakeholders within the rare diseases community in-
clude, but are not limited to, the people affected by rare dis-
eases such as patients, carers, and families, clinicians, allied
health practitioners, social and disability services, research-
ers, universities, advocates, patient support groups, funders,
industry (e.g. pharmaceutical, biotechnology and medical
device companies), regulators and policy-makers. All of
these groups were represented at the symposium.
Previously we have published a summary of the sympo-
sium and some preliminary information on the outcomes
of the workshop discussions, such as the endorsement to
develop a national plan for rare diseases in Australia. [9]
This paper describes in more detail the key issues, goals
and actions that were identified by stakeholders for the de-
velopment of a national plan. The aim of the paper is to be
transparent about the outcomes of the stakeholder work-
shops, how these compare to the content of EUROPLAN
and national plans already developed in other countries
and how the outcomes might be integrated in the ongoing
process of developing a national plan for Australia.
Methods
A workshop was held following each plenary session of
the symposium. The overall objective of these workshops
was to discuss the information presented in the plenary
sessions and identify key issues, goals and actions for the
further development of an Australian national plan for
rare diseases. The topics for the plenary and workshop
sessions were: 1) The development of national plans for
rare diseases; 2) Patient empowerment; 3) Patient care,
support and management; 4) Research and translation; 5)
Networks, partnerships and collaboration; and 6) Moving
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sions included local and international experts in each of
these domains. (For the symposium program see www.rar-
edisease.com.au)
Three workshops (covering the topics of plan develop-
ment, patient empowerment and moving forward post-
forum) involved participants working within broad stake-
holder groups, these being a) patients, carers, advocates,
representatives of patient support organisations; b) scien-
tists, researchers, industry representatives; c) medical,
health, social services; and d) policy-makers, regulators,
academics. The primary rationale behind this approach was
to provide an opportunity for stakeholders to meet other’s
in their group and provide an initial environment where all
stakeholders felt comfortable contributing to discussions.
This was particularly for patients and carers who we per-
ceived might initially be reluctant to express their views in
front of ‘experts’ such as clinicians. The remaining work-
shops involved participants working across stakeholder
groups, where we perceived cross-stakeholder discussions
might be particularly useful (e.g. on the topics of research,
translation, networks, partnerships and collaboration).
Participants selected which table they wanted to join to
partake in discussions. Each table was setup for 8 but could
accommodate a maximum of 10 members. The process for
each workshop involved participants discussing issues
related to the preceding plenary session. A set of broad dis-
cussion guidelines, based on principles of deliberative pub-
lic engagement [18] were provided to participants and
these included the demonstration of respect for each other,
everybody having a chance to talk, active listening, being
willing to provide arguments for and against personal posi-
tions on issues, willing to change personal positions, willing
to work towards consensus on issues and willing to accept
and document any persistent disagreements.
One participant on each table self-selected to scribe and
complete summary sheets of the table discussions. These
sheets requested feedback on key issues for stakeholders,
including those specifically for government and short-term
and long-term goals/actions. All the sheets were collected
by the workshop organizers and immediately following
each workshop session, these were placed on a Feedback
Board that was accessible to all symposium participants,
enabling the broad sharing of discussion outcomes. The
feedback sheets were used as data sources for the findings
reported in this paper. One author (CM) conducted initial
thematic analyses of the feedback, first within each work-
shop session and then across workshop sessions. The the-
matic outcomes of these analyses were then reviewed by all
other authors and are presented in this paper.
Results
Table 1 shows the geographical distribution of the partici-
pants; the majority of symposium participants were fromAustralia and the majority of those not from Australia were
attending as keynote speakers. The stakeholder group with
the greatest number of representatives at the symposium
was people directly affected by rare diseases including
patients, parents and carers, some of whom were formally
representing patient support groups.
Symposium participants identified a range of key issues for
consideration in an Australian national plan for rare diseases,
and each key issue was associated with a number of goals
and actions. The key issues, goals and actions are summar-
ized below under these six major headings: 1) National Plan;
2) Collaboration; 3) Information; 4) Services; 5) Funding.
National plan
The key issue identified by stakeholders was an agreement
that Australia must progress the development of a national
plan for rare diseases. To this end symposium participants
agreed that a set of guiding principles and recommenda-
tions, drawn from the outcomes of the symposium work-
shops, should be used to inform and frame the development
of a national plan. Symposium attendees proposed that an
Australian national plan for rare diseases should be founded
on a human rights approach which promotes equitable ac-
cess to health care for all. The plan should focus on the
common issues that exist across the range of rare diseases
and stakeholders. It should be sustainable, actionable, and
aligned with other national strategies (e.g. disability, prevent-
ive health, chronic disease). The view of participants was
that stakeholder input to the development of a national stra-
tegic plan for rare diseases should be guided and coordi-
nated by a committee that is inclusive of all stakeholder
groups. The strategic planning process should have Federal/
State government agreement and commitment to action,
be supported by national legislationa and include processes
for inclusive, continuing stakeholder consultation and
Molster et al. Orphanet Journal of Rare Diseases 2012, 7:50 Page 4 of 10
http://www.ojrd.com/content/7/1/50engagement, which should inform and lead to the devel-
opment of an implementation plan with timelines and
processes for the monitoring, evaluation and review of the
national plan’s goals and outcomes.
Collaboration
The key issues identified in the area of collaboration were:
 A national, umbrella organisation should be
established for rare diseases in Australia using best
practice principles of governance. The organisation
should be inclusive of all stakeholders in the rare
diseases sector.
 Strong stakeholder networks are required national
and internationally.
Peak body
Symposium participants were universal in their support
for the development of a national umbrella organisation
for rare diseases. This was perceived to provide a national
peak body and inclusive network that could undertake
roles and functions such as the following; provide a single
united voice for rare diseases; identify common issues and
significant unmet needs of the rare diseases community;
develop policy and position papers; raise public awareness;
coordinate activities and events at a national level (e.g.
Rare Disease Day); administer and coordinate a central
“one-stop” website for information and educational mate-
rials; advocate, lobby and provide advice to government
agencies, policy makers and politicians on the needs of the
rare disease community; establish links with similar orga-
nisations internationally; set up and administer a national
rare diseases registry; and provide a central hub to help
co-ordinate and facilitate links amongst organisations at
local, state, national and international levels.
A potential challenge identified by the workshop partici-
pants was how to establish the structure of a peak body.
In particular, how to establish a core leadership group
around which all stakeholders could unite as the ‘single
voice’ for rare diseases and thereby promote a coordinated,
national approach.
Networks
The need for collaboration and networking was strongly
expressed. In particular, symposium participants recom-
mended that a formal, overarching Australian network for
rare diseases should be established, similar to the European
Organization for Rare Diseases (EURORDIS) and the U.S.
National Organization for Rare Diseases (NORD). At the
same time, existing networks should be recognized and
valued (e.g. international, national and state based support
groups and disease-specific coalitions such as TREAT-
NMD). Greater collaborations and functional linkages were
also seen to be required within and across Federal, stateand local government departments and jurisdictions (e.g.
health, finance, commercial services, transport, disability,
employment). It was perceived that this might reduce “red
tape” and enable more efficient and effective allocation of
funding and utilization of existing resources.
According to symposium participants, collaborations and
networks should be premised on open communication and
the equal and inclusive engagement of all stakeholders, with
the voices of patients, carers and families at the core of all
decision-making processes. Strategies may be required to
develop stakeholder solidarity, identify common ground,
and reach consensus. Potential issues identified by partici-
pants included the presence of “territorialism” and “silos”,
conflicting interests and expectations and the need to en-
sure that individual stakeholders (particularly disease-
specific support organisations) are able to maintain their
own identity.
Information
The key issues identified in terms of information, data
and evidence were:
 A standard definition of “rare diseases” is required
for Australia. Preferably this would have
international agreement.
 Publicly available information on rare diseases is
needed for patients, families, health professionals,
researchers, policy makers and other stakeholders.
 Awareness, education and engagement programs are
required for the general public, health and other
service professionals, government agencies,
politicians and all other stakeholders.
 Politicians, governments and research bodies need
to be lobbied in a coordinated way that is
empowering for people affected by rare diseases.
 Australian evidence is needed to inform strategic
planning, funding allocation decisions and
research.
 Australian-based registries are required for rare
disease groups and the rare disease community
overall.
 Audits are required to identify “the current
situation” in Australia with regards to rare diseases
and “good practice models”.
Public information
Symposium attendees identified the need for publicly
available information on rare diseases to be easily access-
ible, centralized (e.g. a “one-stop shop” web portal/website
or joining Orphanet and developing Australian and New
Zealand specific content pages to link to this site), concise,
reliable, accurate, up-to-date, easy to understand, and dis-
ability “friendly”. It was suggested that the types of infor-
mation that should be easily accessible include: disease
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of specialists; local medical and social services; entitle-
ments (e.g. financial); and support groups.
The need for increased public awareness, education and
engagement programs was consistently suggested by sym-
posium participants. These programs were perceived to
offer outcomes that included; a raised profile of rare dis-
eases as an aggregate category of diseases with a range of
common issues; awareness of the rights and stereotypes of
people affected by rare diseases; and recognition of the im-
pact of rare diseases as a significant public health issue and
priority area for State and Federal government support and
funding.
Lobbying
Lobbying and the dissemination of information to politi-
cians and the public service was seen to be crucial to
achieving several outcomes, including; bi-partisan political
support; government recognition of the personal, social and
financial impact of rare diseases on families; recognition of
economic costs and need for planning; and recognition of
rare diseases as a national health and research priority area.
Engagement with professional lobbyists and high profile
sponsors, opinion leaders and “champions” in business and
government was identified as important for effective lobby-
ing. At the same time patient and carer champions and
ambassadors should be supported and enabled to advocate
for themselves.
Australian research and evidence
Symposium participants indicated Australia needs a na-
tional framework for research on rare diseases. They also
suggested that Australian-based researchers and research
institutions across academia, clinical practice, government
and industry must collaborate and work together to be
most effective in conducting multi-disciplinary research on
rare diseases (e.g. identifying sufficient cases for clinical
trials). Patients, carers and families should be directly
involved in decisions about research on rare diseases.
Suggested priority areas for research included: quality of life
and social impact studies (e.g. needs of patients/carers); epi-
demiology and health economics (e.g. prevalence of rare
diseases, burden of disease, cost-effectiveness of treatments
and health services); and clinical trials (e.g. drug trials, novel
therapies). Translating research into better prevention, early
intervention, diagnosis and treatment to improve health
and quality of life outcomes was also identified as a pri-
ority. It was suggested that this requires the integration
of research activity within the clinical context.
In Australia the National Health and Medical Research
Council (NHMRC) is the peak agency for funding health
and medical research. Symposium participants suggested
that the NHMRC must recognise the value of research on
rare diseases and allocate funding accordingly. Public/private collaborations and funding mechanisms should also
be explored. Stakeholders also suggested that data collec-
tion by governments (State and Federal) be standardized
so that information can be exchanged and aggregated
across jurisdictions. Participants identified a range of po-
tential barriers in relation to data sharing, including ethical
issues and policy requirements for health systems in differ-
ent jurisdictions, privacy and confidentiality issues inherent
in data linkage and ownership of the aggregated data. Sta-
keholders expressed that, in areas such as clinical trials,
bureaucracy needs to be minimized and the co-ordination
of multi-institutional and/or multi-State research needs to
be improved, including uniform ethics approval processes.
Similarly, novel approaches to research may be required,
and should be supported by funding bodies. For example,
the low prevalence of most rare diseases means that the
placebo/double blind trial design required by regulatory
bodies is usually not possible and innovative trial designs
should be recognized for rare diseases. Finally, stronger re-
search training, career pathways and the attraction and re-
tention of research expertise are required.
Audits
A range of “audits” were recommended as a means of col-
lating information on the current situation in Australia to
identify: common issues and unmet needs across rare dis-
eases; the full range of stakeholders; key individuals and
organisations; existing expertise and perceived gaps in ex-
pertise; existing networks, partnerships, clinical and other
services, programs and systems; registries (disease groups
with and without them); research and research facilities
(including clinical trials); funding mechanisms; informa-
tion, education and training resources; and challenges for
people affected by rare diseases, in particular, those who
live in rural and remote areas of Australia. It was perceived
that strategic plans should be developed and implemented
to address any gaps and inefficiencies as well as identifying
opportunities to link existing agencies, organisations,
groups and programs to achieve synergies and capture
economies of scale.
Services
The key issues identified in the areas of services and
support for people affected by rare diseases, were:
 All patients, carers and families should have equal
access to programs and services.
 A generic (overarching) model of care (or clinical
pathway) for rare disease is required. b
 Streamlined, coordinated whole-of-lifetime service
provision is required.
 A case co-ordination approach is required that
encompasses all services relevant to patients, carers
and families affected by rare diseases. This includes
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specialists, GPs etc.), education, disabilities,
employment, local community services and social
support services.
 Diagnosis needs to be early, accurate and accessible
for all Australians.
 Effective, direct communication and information
sharing across health services and health
professionals (e.g. GPs, specialists); and between
health professionals and patients, carers and families
is critical to quality of life and clinical care
outcomes.
 Health professionals need more awareness and
support in relation to rare diseases. This is
particularly for GPs but also for medical students,
specialist clinicians and allied health professionals
 Patients, carers and families affected by rare diseases
need support.
 Existing support groups should be strengthened and
new groups established for diseases that currently do
not have a support group.
Coordinated whole-of-lifetime care
Symposium participants expressed the view that there
should be no gaps in service delivery across the lifespan of
an individual; programs and services should seamlessly
span transitions from pediatrics to adulthood to aged care.
To facilitate this, it was suggested that case coordinators
are needed who will be the first point of contact for
patients, carers and families. Case coordination should:
have an individualized needs-driven focus (not a disease
focus); emphasize flexibility, integration, cost effectiveness
and cost efficiencies for the health system; and be founded
on national best practice standards and/or model of care
for rare diseases. It was perceived that a generic model(s) of
care could focus on problems common to many types of
rare diseases; and address all aspects of care including diag-
nostic services, treatment options, multi-disciplinary com-
munication and service integration. It was also perceived
that multi-disciplinary clinic(s) could facilitate case coordin-
ation. Such centers could undertake various roles including;
establishing and managing clinical networks; acting as
reference centers and centers of excellence that provide
diagnosis, treatment, advice, follow-up care, information
and entitlements in a coordinated cross-jurisdictional (e.g.
state-state, state-national) manner.
All workshop groups expressed the view that patients
must have fair and equitable access to services, programs
and treatments (including novel, innovative and/or trial
treatments), and that the availability of therapies and gen-
etic testing must be improved. Specifically, gaps in service
delivery were perceived to exist across States and for those
in rural and remote areas. It was suggested that genetic
testing for rare diseases should be covered by Medicare(a national government initiative that delivers programs
such as the Australian Pharmaceutical Benefits Scheme)
and support should be provided for “not-yet-diagnosed”
patients and families. The symposium participants also
suggested the system for determining the cost of and reim-
bursement for orphan drug treatments needs to be chan-
ged. Some suggested options include: using a different
approach, or alternative pathway, to determine access to
rare disease drugs, rather than the existing Life Saving
Drugs Program or Pharmaceutical Benefits Scheme; intro-
duce a Rare Diseases Act; and/or identifying the Australian
community’s values regarding access to orphan drugs and
how much, as taxpayers, they are willing to pay for medi-
cines to treat those living with a rare disease.
Information sharing
Within the context of service delivery, symposium partici-
pants held the view that patients, carers and families need
access to information from health professionals that is up-
to-date, accurate, reliable and easy to understand. At the
same time, health professionals should keep an open mind
about therapies and treatments which may impact on rare
diseases and listen to patients’ stories about what works.
The knowledge and expertise of patients, carers and fam-
ilies should be acknowledged and respected. System(s) are
also required that will enable the sharing of clinical and
other health information within and across health services,
health professions and other relevant service providers (e.g.
disability services). Examples of suggested systems include
e-health records, a privacy-protected website that records
patient details and recommended/adopted clinical pathway
approaches and a central repository of patient action plans.
Greater sharing of service-user information would further
enable more effective case coordination and whole-of-
lifetime service delivery.
Support for health professionals
Health professionals are perceived to need greater support
to provide effective services for those affected by rare dis-
eases. Examples of suggested approaches to support include:
the provision of resources and tools (e.g. referral/diagnostic
tools for GPs, education programs); primary health care
partnerships; national training packages; rare diseases being
included in medical training curriculum; standardized pro-
tocols for the delivery of clinical information and better
awareness of and access to information (e.g. Orphanet).
Support for people affected by rare diseases
Patients, carers and family members are perceived to need
improved support services. It was suggested that the types
of support may include: support groups and local contacts;
medical aids; education/information; employment and
alternatives to employment; supported accommodation;
respite services; mental health and psycho-social support;
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physical access to services).
Participants suggested that support groups should be
valued and assisted, either financially or in-kind, by other
stakeholders. This was in a range of areas such as funding,
best-practice governance, business management, strategic
planning, marketing and fundraising. It was also indicated
that support groups should be accredited. This would re-
quire support groups to meet best practice standards for
governance and business management.
Funding
Symposium participants proposed the need for funding to
be sustainable and patient-focused, that is, funding should
address the needs of patients, carers and families affected
by a rare disease. A range of sources of funding and infra-
structure should be considered (e.g. government, industry,
community groups, not-for profit groups, philanthropists,
and public-private partnerships between academia, indus-
try, government and community groups).
Improved funding was perceived to be critical to the de-
velopment and implementation of a national plan on rare
diseases. Symposium participants suggested funding is
required in a range of areas such as:
 Research, for example: to provide incentives for
national and international collaboration; incentives
to encourage industry (e.g. marketing exclusivity;
research scholarships; seed funding to start research
projects; translational research; health economic
studies; quality of life studies and reimbursement of
patients’, carers’ and family research costs).
 Infrastructure, for example: for research; enabling
grants; to build critical mass and to establish registries
 GP services, for example: to provide GP incentives
to support patients/families with complex needs.
 Clinical and other services, for example: genetic
testing and diagnostic services; care and treatment
planning; incentives to take on patients/families with
complex needs; training positions and specialists in
public hospitals.
 Support groups and organizations, for example: seed
capital to fund project officers; ongoing funding for
an umbrella organisation; administration support;
conference attendance and website development.
Discussion
The views expressed by participants at the inaugural Austra-
lian Rare Diseases Symposium indicate widespread support
for a national plan for rare diseases in Australia, among a
range of stakeholder groups in the rare diseases community,
including patients, carers, clinical and disability services, aca-
demia and the biotechnology/pharmaceutical industry. There
also appears to be general agreement on a range of keyissues, goals and actions for inclusion in a national plan, in-
cluding the need for a peak body for rare diseases, networks
of stakeholders, Australian research and evidence on rare
diseases, public information and education and accessible,
integrated services.
The outcomes of the symposium workshops (i.e., key
issues, goals, actions for a national plan) are consistent
with the findings from an earlier stakeholder survey con-
ducted by the National Rare Diseases Working Group
(NRDWG) convened by the Australian Pediatric Surveil-
lance Unit (APSU) [10,13]. They are also consistent with
findings, frameworks and initiatives being undertaken
internationally (such as EUROPLAN), and with the aims
and priorities of national plans in other countries including
Belgium, Bulgaria, Czech Republic, Germany, Greece,
Luxembourg, Portugal, Romania and Spainc [6]. This is in
areas including mechanisms for facilitating patient em-
powerment, such as a peak body [19,20] and web-based in-
formation and networking resources [19,21-23]; the need
for reliable epidemiological data; the need for registries to
facilitate clinical research, public health surveillance, and ser-
vice/program evaluation [24]; and the need for research
infrastructure, including partnerships and collaborations, re-
search sites with common protocols and multi-disciplinary
research teams [3,5,7,25-31]. Similar to stakeholders in other
countries, symposium participants acknowledged the com-
plexities of implementing some of these actions. This is par-
ticularly in the area of research, with issues such as small
patient populations meaning constraints in epidemiologic re-
search and low -powered clinical trials; limited clinical data
and biological specimens, which limits studies of disease
causes and mechanisms; a low interest from the pharmaceut-
ical industry due to a limited market incentives (low return
on investment); and a limited number of experts and clini-
cians committed to the study of rare diseases [32].
There also appear to be similarities with other countries
with respect to accessing timely, correct diagnosis; inte-
grated diagnostic pathways, case-coordination of multi-
disciplinary care; national centers of excellence; clearly
defined diagnostic guidelines; quality information; awareness
among health professionals of rare diseases; support for
carers; and treatments including orphan drugs [1,19,26,33-
38]. A key implication, of the workshop outcomes being
consistent with international approaches to rare diseases, is
that in developing an Australian national plan it seems
plausible to draw on frameworks for plan development that
have been proposed for use in other jurisdictions, such as
EUROPLAN. This might enable planners in Australia to
benefit from the experience of those who have already devel-
oped national plans and minimise any unnecessary re-
inventing of the wheel (a preferred outcome expressed by
stakeholders at the symposium).
The translation of the symposium outcomes to govern-
ment policy (i.e., a national plan) requires the consideration
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keholders were represented at the symposium, it should
nonetheless be acknowledged that some stakeholder groups
(e.g. clinicians) appeared less well represented than other
groups (e.g. support group members, researchers). The
symposium findings are thus limited, to the extent that
those not present at the symposium may hold different
views from those views expressed by the symposium parti-
cipants. Hence, in the assessment of the unmet needs of
the rare diseases community and as jurisdictions consider
the development of a national plan, it will be important to
monitor which stakeholder groups engage most strongly
and develop strategies and a range of mechanisms for en-
couraging participation by all stakeholders. These might in-
clude, for example, online discussions, written submissions,
in-depth interviews, surveys and forums. Ongoing, systemic
stakeholder engagement in the planning process, as identi-
fied by the participants in the symposium engagement, will
be critical to the successful development and implementa-
tion of an Australian national plan for rare diseases.
Secondly, some issues and goals identified by symposium
participants could be viewed as “motherhood” notions, in
that little detail was provided as to how the issue or goal
might be implemented, or what barriers or limitations to
implementation might exist. For example the implementa-
tion of integrated, coordinated care and multi-disciplinary
teams would likely require the consideration of a range of
challenges, which in our view need to be explored before
such systemic changes could be put forward as part of a na-
tional plan on rare diseases. As noted by several authors
[39,40] evidence-based policy options are required, along
with information on the scope of challenges, barriers to
and potential positive outcomes of integrated, coordinated
care and what methods would be most effective for meas-
uring the outcomes of such healthcare delivery. Further the
concept of integration is contested, so clarification is needed
of the terminology and the meaning attributed by stake-
holders to the concept. Specifically, further investigation is
required into what integration would look like from each
stakeholder’s point of view, including the patient, clinical
practice, public health and disability service perspectives.
The literature notes that other issues also require greater
clarity of terminology including the concept of ‘rare dis-
eases’ itself. A European study indicates the term does not
have a common meaning across all stakeholders and is
meaningless for clinicians [41]. Making assumptions that all
stakeholders have similar understandings of the symposium
outcomes, simply because they used the same terminology
to arrive at those outcomes, might be problematic for the
development of a national plan. One starting point for the
standardization of terminology is the adoption of an inter-
nationally consistent definition of rare diseases. To this end the
following definition adapted from the European Commission
Directorate General for Health and Consumers Public Healthpolicy, d and more recently used by European countries devel-
oping their national rare disease plans, [42] has been proposed
as the definition in Australia:
A rare disease is any disorder or condition that is a life-
threatening or chronically debilitating disease which is sta-
tistically rare, with an estimated prevalence of less than 5 in
10,000 or of similarly low prevalence and high level of com-
plexity that special combined efforts are needed to address
the disorder or condition.
Conclusions
In Australia several of the components relevant to a national
plan for rare diseases are already in existence or being estab-
lished. For example policy and planning is in place for
chronic diseases and disability services, people with rare
diseases utilize genetic and other clinical services and spe-
cializations, and a number of patient registries, biobanks,
bioinformatics and genetic technologies are operational.
Notwithstanding this there are a number of areas which if
better understood and coordinated into a specific national
plan might bring great benefits to the rare disease commu-
nity. Planning in the rare disease setting is also likely to
translate to benefits for tackling common multi-genic dis-
orders among the broader chronic disease community
including advances in pharmacogenomics (personalised
medicine) [43-45]. To progress national planning we
believe some form of prioritization, of the key issues, goals
and actions identified by symposium participants, is
required. In our view, conducting evidence-gathering ac-
tivities, such as audits of the current situation regarding
rare diseases in Australia, is a good starting point for fill-
ing gaps in knowledge and achieving other goals and
actions identified by symposium participants. In line with
the views of other authors [3-5,29-31,46,47] we contend
that the acquisition of evidence provides a necessary step
in a comprehensive planning approach.
Endnotes
aThe use of the terms generic and model of care and
clinical pathways require definitions, but was meant to
indicate the need to have a map or plan for the process
of diagnosis, follow-up counselling, treatment etc.
bThe use of the terms generic and model of care and
clinical pathways require definitions, but was meant to
indicate the need to have a map or plan for the process
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